BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20736744)

  • 21. A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.
    Qu X; Randhawa G; Friedman C; O'Hara-Larrivee S; Kroeger K; Dumpit R; True L; Vakar-Lopez F; Porter C; Vessella R; Nelson P; Fang M
    Cancer Genet; 2013; 206(1-2):1-11. PubMed ID: 23352841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues.
    Tu JJ; Rohan S; Kao J; Kitabayashi N; Mathew S; Chen YT
    Mod Pathol; 2007 Sep; 20(9):921-8. PubMed ID: 17632455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.
    Jenkins RB; Qian J; Lieber MM; Bostwick DG
    Cancer Res; 1997 Feb; 57(3):524-31. PubMed ID: 9012485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies.
    Takahashi S; Qian J; Brown JA; Alcaraz A; Bostwick DG; Lieber MM; Jenkins RB
    Cancer Res; 1994 Jul; 54(13):3574-9. PubMed ID: 8012984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimum altered regions in early prostate cancer progression identified by high resolution whole genome tiling path BAC array comparative hybridization.
    Watson SK; Woolcock BW; Fee JN; Bainbridge TC; Webber D; Kinahan TJ; Lam WL; Vielkind JR
    Prostate; 2009 Jun; 69(9):961-75. PubMed ID: 19267368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
    Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
    Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
    Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA
    J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.
    Rajput AB; Miller MA; De Luca A; Boyd N; Leung S; Hurtado-Coll A; Fazli L; Jones EC; Palmer JB; Gleave ME; Cox ME; Huntsman DG
    J Clin Pathol; 2007 Nov; 60(11):1238-43. PubMed ID: 17259299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
    Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
    J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions.
    Cerveira N; Ribeiro FR; Peixoto A; Costa V; Henrique R; Jerónimo C; Teixeira MR
    Neoplasia; 2006 Oct; 8(10):826-32. PubMed ID: 17032499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Production of serum-free and total prostate-specific antigen due to prostatic intraepithelial neoplasia.
    Minardi D; Galosi AB; Dell'Atti L; Hanitzsch H; Mario P; Muzzonigro G
    Scand J Urol Nephrol; 2002; 36(5):323-9. PubMed ID: 12487735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management.
    Shah RB
    Adv Anat Pathol; 2013 Mar; 20(2):117-24. PubMed ID: 23399797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer.
    Sinha AA; Quast BJ; Reddy PK; Lall V; Wilson MJ; Qian J; Bostwick DG
    Exp Mol Pathol; 2004 Oct; 77(2):153-9. PubMed ID: 15351240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.
    Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM
    Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer: a pilot study.
    Sun QP; Li LY; Chen Z; Pang J; Yang WJ; Zhou XF; Qiu JG; Su ZL; He D; Gao X
    J Mol Diagn; 2010 Sep; 12(5):718-24. PubMed ID: 20616363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization.
    Qian J; Bostwick DG; Takahashi S; Borell TJ; Herath JF; Lieber MM; Jenkins RB
    Cancer Res; 1995 Nov; 55(22):5408-14. PubMed ID: 7585610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
    Tomlins SA; Laxman B; Dhanasekaran SM; Helgeson BE; Cao X; Morris DS; Menon A; Jing X; Cao Q; Han B; Yu J; Wang L; Montie JE; Rubin MA; Pienta KJ; Roulston D; Shah RB; Varambally S; Mehra R; Chinnaiyan AM
    Nature; 2007 Aug; 448(7153):595-9. PubMed ID: 17671502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer.
    Wang J; Cai Y; Ren C; Ittmann M
    Cancer Res; 2006 Sep; 66(17):8347-51. PubMed ID: 16951141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer.
    Doak SH; Jenkins SA; Hurle RA; Varma M; Hawizy A; Kynaston HG; Parry JM
    Cancer Genet Cytogenet; 2007 Jul; 176(2):161-5. PubMed ID: 17656261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.